Manufacturing & Packaging

New PC column explores commercialization trends and how pharma can adjust to the new squeeze of market, regulatory, pricing, and gross-to-net pressures.

Company’s latest report reveals future plans, powered by efforts to divert more of its air shipments to sea.

New fill-finish plant strengthens nation’s reputation as an APAC biomedical hub.

Document reveals that 20 of 28 of participating Big Pharma manufacturers saw their DIO increase by an average of 5%, suggesting that large amounts of inventory do not necessarily offer protection from running low on medication.

The treatments span various therapeutic areas, from antibiotic to oncology.

New capability will support manufacturing of commercial-stage therapies to help combat cancers and genetic diseases.

Roundtable drills down on ways the two sectors can come together to reduce carbon emissions.

Real-time location monitoring solution allows increased visibility into the precise location of shipments in transit globally.

CDMO’s fill-finish line offers batch capacity of over 200,000 syringes.

Company will also financially commit $15 million for those pursuing pharma manufacturing careers.

Merger with pharmacovigilance service provider helps company expands its end-to-end solutions in the region.

Demands for services in this sector have increased since last year’s Q1 Scientific acquisition, CDMO says.

Bourgoin hub broadens customer needs to also address commercial manufacturing.

Network aims to improve end-to-end supply chain visibility for the life sciences industry.

New facility—located on company’s Pennsylvania site—is part of three-part manufacturing contract with BARDA.

Rise in value attributed to the ongoing decentralization of pharmacies.

Q&A explores new opportunities to strengthen supply chain resilience—and build on the lessons learned.

Project addresses customer demand in GMP-powered advanced therapeutics.

New site is expected to complement CDMO’s commercial production experience.

Acquisition expands company’s eCTD submission capabilities.

Hoping to accelerate the drug delivery process, production is expected to begin as early as 2025.

Following numerous successful trial runs, vaccine production is expected to reach 700 million.

Expansion expected to increase global capacity by 75%.

Joint venture revolves around around the use of raw materials for the development—and ultimately commercialization—of therapies.

New 25,000 square-foot facility will help grow customers’ gene therapy programs.